Literature DB >> 12960297

Cutting Edge: Multiple autoimmune pathways in kd/kd mice.

Wayne W Hancock1, Tsai-Lung Tsai, Michael P Madaio, David L Gasser.   

Abstract

The kidney disease (kd) mutation was transferred to a C57BL/6 (B6) background by selection for closely linked microsatellite markers. The resulting congenic strain, B6.kd, was mated with partners homozygous for targeted mutations of CD4, CD8, CD28, IL-2, recombinase-activating gene-1 (Rag-1), ICAM-1, or beta(2)-microglobulin. In most of the resulting double mutants, kidney disease occurred as readily and as severely as in the B6.kd controls, although disease occurred somewhat less frequently in age-matched CD28(-/-) kd/kd mice. Immunohistology demonstrated a predominance of macrophages in the lesions of B6.kd and most of the double mutants, with the remaining cells consisting of T cells and variable numbers of NK cells. In Rag-1(-/-) kd/kd, approximately 50% of infiltrating cells were macrophages, and approximately 50% were NK cells. These results suggest that the initial lesion caused by the mutant gene is intrinsic to the kidney and that the immune response that subsequently occurs can involve any one of several different cellular compositions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12960297     DOI: 10.4049/jimmunol.171.6.2778

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Cross-platform expression microarray performance in a mouse model of mitochondrial disease therapy.

Authors:  Zhe Zhang; David L Gasser; Eric F Rappaport; Marni J Falk
Journal:  Mol Genet Metab       Date:  2009-10-30       Impact factor: 4.797

2.  An overview of current mouse models recapitulating coenzyme q10 deficiency syndrome.

Authors:  Floriana Licitra; Hélène Puccio
Journal:  Mol Syndromol       Date:  2014-07

3.  The mitochondrial and kidney disease phenotypes of kd/kd mice under germfree conditions.

Authors:  Troy M Hallman; Min Peng; Ray Meade; Wayne W Hancock; Michael P Madaio; David L Gasser
Journal:  J Autoimmun       Date:  2005-12-06       Impact factor: 7.094

4.  Glomerular and tubular epithelial defects in kd/kd mice lead to progressive renal failure.

Authors:  Michael P Madaio; Rexford S Ahima; Ray Meade; Daniel J Rader; Alberto Mendoza; Min Peng; John E Tomaszewski; Wayne W Hancock; David L Gasser
Journal:  Am J Nephrol       Date:  2005-11-09       Impact factor: 3.754

5.  The kd/kd mouse is a model of collapsing glomerulopathy.

Authors:  Laura Barisoni; Michael P Madaio; Maria Eraso; David L Gasser; Peter J Nelson
Journal:  J Am Soc Nephrol       Date:  2005-08-24       Impact factor: 10.121

6.  Coenzyme Q10 supplementation rescues renal disease in Pdss2kd/kd mice with mutations in prenyl diphosphate synthase subunit 2.

Authors:  Ryoichi Saiki; Adam L Lunceford; Yuchen Shi; Beth Marbois; Rhonda King; Justin Pachuski; Makoto Kawamukai; David L Gasser; Catherine F Clarke
Journal:  Am J Physiol Renal Physiol       Date:  2008-09-10

7.  Mutant prenyltransferase-like mitochondrial protein (PLMP) and mitochondrial abnormalities in kd/kd mice.

Authors:  Min Peng; Leonard Jarett; Ray Meade; Michael P Madaio; Wayne W Hancock; Alfred L George; Eric G Neilson; David L Gasser
Journal:  Kidney Int       Date:  2004-07       Impact factor: 10.612

8.  Focal segmental glomerulosclerosis is associated with a PDSS2 haplotype and, independently, with a decreased content of coenzyme Q10.

Authors:  David L Gasser; Cheryl A Winkler; Min Peng; Ping An; Louise M McKenzie; Gregory D Kirk; Yuchen Shi; Letian X Xie; Beth N Marbois; Catherine F Clarke; Jeffrey B Kopp
Journal:  Am J Physiol Renal Physiol       Date:  2013-08-07

9.  Primary coenzyme Q deficiency in Pdss2 mutant mice causes isolated renal disease.

Authors:  Min Peng; Marni J Falk; Volker H Haase; Rhonda King; Erzsebet Polyak; Mary Selak; Marc Yudkoff; Wayne W Hancock; Ray Meade; Ryoichi Saiki; Adam L Lunceford; Catherine F Clarke; David L Gasser
Journal:  PLoS Genet       Date:  2008-04-25       Impact factor: 5.917

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.